Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. (Q54566911)

1 June 2018

title

Long-term chemotherapy may prolong survival in advanced non-small-cell lung cancer among responders to first-line chemotherapy. (English)

1 reference

1 June 2018

1 reference

Tomonori Hirashima

1

1 reference

1 June 2018

Hidekazu Suzuki

2

1 reference

1 June 2018

Masashi Kobayashi

3

1 reference

1 June 2018

Youko Kondoh

4

1 reference

1 June 2018

Yoshie Tokuoka

5

1 reference

1 June 2018

Yuka Matsuura

6

1 reference

1 June 2018

Motohiro Tamiya

7

1 reference

1 June 2018

Naoko Morishita

8

1 reference

1 June 2018

Shinji Sasada

9

1 reference

1 June 2018

Norio Okamoto

10

1 reference

1 June 2018

Kohei Akazawa

11

1 reference

1 June 2018

Ichiro Kawase

12

1 reference

1 June 2018

publication date

19 August 2011

1 reference

1 June 2018

published in

Medical Oncology

1 reference

1 June 2018

volume

29

1 reference

1 June 2018

issue

3

1 reference

1 June 2018

page(s)

1629-1637

1 reference

1 June 2018

cites work

Cancer statistics, 2009

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Regional lymph node classification for lung cancer staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Duration of chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Cost-effectiveness of second-line chemotherapy for non-small cell lung cancer: an economic, randomized, prospective, multicenter phase III trial comparing docetaxel and pemetrexed: the GFPC 05-06 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-011-0034-6

Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21853345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21853345

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-011-0034-6

1 reference

1 June 2018

1 reference

1 June 2018